期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
Comparison of long-lasting therapeutic effects between succimer and penicillamine on hepatolenticular degeneration 被引量:3
1
作者 REN Ming Shan, ZHANG Zhi, WU Jun Xia, LI Fei, XUE Ben Chun and YANG Ren Min 《World Journal of Gastroenterology》 SCIE CAS CSCD 1998年第6期75-77,共3页
AIM To compare the long term effect of succimer (Suc) with that of penicillamine (Pen) in treating hepatolenticular degeneration (HLD). METHODS One hundred and twenty patients with HLD were divided into 2 groups. ... AIM To compare the long term effect of succimer (Suc) with that of penicillamine (Pen) in treating hepatolenticular degeneration (HLD). METHODS One hundred and twenty patients with HLD were divided into 2 groups. Group A ( n =60) received Suc 750mg , po. bid. Group B ( n =60) received Pen 250mg , po. qid. The period of maintenance treatment varied from 6 months to 3 years, averaging 1 5 years. Symptoms and therapeutic effects were evaluated by modified Goldstein scale. RESULTS The total effectiveness of group A in two different periods of treatment were 80% and 85% respectively, higher than those of group B (58% and 59% respectively) ( P <0 05). Suc also had obvious curative effects for the patients who failed in the use of Pen. There were fewer side effect in group A than in group B ( P <0 05). Suc and Pen could increase urinary copper excretion effectively and continually. CONCLUSION Suc is more effective and safer than Pen. Clinically, it can replace Pen as first choice drug for long term maintenance therapy of HLD. 展开更多
关键词 hepatolenticular degeneration/drug THERAPY succimer/therapeutic use penicillamine/therapeutic use
下载PDF
Functional dyspepsia of ulcer-dysmotility type:clinical incidence and therapeutic strategy 被引量:3
2
作者 WANG XiaoZhong and LIN GuZhen 《World Journal of Gastroenterology》 SCIE CAS CSCD 1998年第4期95-96,共2页
Functionaldyspepsiaofulcerdysmotilitytype:clinicalincidenceandtherapeuticstrategyWANGXiaoZhongandLINGuZhe... Functionaldyspepsiaofulcerdysmotilitytype:clinicalincidenceandtherapeuticstrategyWANGXiaoZhongandLINGuZhenSubjectheaadings... 展开更多
关键词 dyspepsia/drug therapy famotidine/therapeutic use cisapride/therapeutic use peptic ULCER gastrointestinal motility
下载PDF
The role of drug utilization evaluation in medical sciences
3
作者 Ruby Gangwar Arvind Kumar +2 位作者 Abrar Ahmed Zargar Amit Sharma Ranjeet Kumar 《Global Health Journal》 2023年第1期3-8,共6页
Background:Drug utilization evaluation(DUE)is defined by the World Health Organization(WHO)and focuses on the medical,social,and economic consequences of pharmaceutical marketing,distribution,prescribing,and usage in ... Background:Drug utilization evaluation(DUE)is defined by the World Health Organization(WHO)and focuses on the medical,social,and economic consequences of pharmaceutical marketing,distribution,prescribing,and usage in society.The WHO recommends a physician to every 1000 people.According to the recent data from the Health Ministry in 2019,in which 1.16 million doctors are of active population with just 80%,or 0.9 million,practicing.As a result,a ratio of 0.68 doctors for every 1000 people,which is much below as per the WHO reports.This article describes history,types,WHO guidelines,need and purpose of DUE.Objective:The main aim of this paper is to provide information about the rational use of medication in outpa­tient and inpatient department with special emphasis of DUEs.It also provides awareness directly to healthcare professionals,researchers,academicians,pharmacist and nurses to reduce the irrationality of medicines.Methods:The method used to compile this review information gathered from websites,Google scholar,PubMed,Research gate,and studies published on DUE from July 20 to Oct 22 were included as source of information.Results:We studied more than 35 published study on DUE,that reveals most of the physicians prescribed branded drugs not generic drugs,but WHO prescribing indicator allows to prescribe generic drugs in the hospital pharmacy to maintain better inventory control.It may also help to prevent pharmacist misunderstanding during dispensing.Conclusion:The use of generic prescription names avoids the possibility of medication product duplication and lowers patient costs.It is important to remember that incorrect medication prescriptions have impact on both patients and their family members.WHO indicators identify irrational prescribing behaviours to make therapy more rational and cost-effective. 展开更多
关键词 Anatomical therapeutic chemical classification drug utilization evaluation Prescribing indicators Pregnancy risk classification Rational use of the drug
下载PDF
Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected nonresponders and relapsers after interferon alfa-2a monotherapy 被引量:19
4
作者 Perdita Wietzke-Braun Volker Meier +1 位作者 Felix Braun Giuliano Ramadori 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第2期222-227,共6页
AIM To report on the efficacy, safety and tolerability of interferon alfa-2a combined with a "low dose" of ribavirin for relapsers and non responders to alpha interferon monotherapy.METHODS Thirty-four chron... AIM To report on the efficacy, safety and tolerability of interferon alfa-2a combined with a "low dose" of ribavirin for relapsers and non responders to alpha interferon monotherapy.METHODS Thirty-four chronic hepatitis C virus-infected non-responders to interferon alfa2a monotherapy (a course of at least 3 months treatment) and 13 relapsers to interferon alfa 2a monotherapy (a dose of 3 to 6 million units three times per week for at least 20 weeks but not more than 18 months) were treated with the same dose of interferon alfa-2a used before (3 to 6 million units three times per week) and ribavirin (10 mg/ kg daily) for 6 months. In complete responders, interferon alfa-2a was administered for further 6 months at the same dose used before as monotherapy.RESULTS Seven (20.6%) of 34 non-responders stopped the combined therapy due to adverse events, including two patients with histological and clinical Child A cirrhosis. In 17/27 (63%)non-responders, the combined therapy was stopped after three months because of non-response. Ten of the 27 non-responders completed the 1;2-month treatment course. At a mean follow up of 28 months (16- 37 months)after the treatment, 4/10 (15%) previous non-responders still remained complete responders,All 13 previous relapsers completed the 12-month treatment course. At a mean follow up of 22months (9 - 36 months) after treatment, 6/13(46%) the previous relapsers were stillsustained complete responders.CONCLUSION Our treatment schedule of the combined therapy for 6 months of interferon alfa2a with a low dose of ribavirin (10 mg/kg/day)followed by 6 months of interferon alfa-2amonotherapy is able to induce a sustainedcomplete response rate in 15% of non-responders and 46% of relapsers with chronic hepatitis C virus-related liver diseases comparable to those obtained with the standarddoses of ribavirin 1000 - 1200 mg/day.Randomized prospective controlled trials using lower total amounts of ribavirin in combination with interferon should be performed. 展开更多
关键词 hepatitis C chronic/drug therapy INTERFERON alpha-2a/therapeutic use INTERFERON alpha-2a/administration & DOSAGE ribavirin/administration & DOSAGE ribavirin/therapeutic use
下载PDF
Treatment of rotaviral gastroenteritis with Qiwei Baizhu powder 被引量:7
5
作者 Shuang-Teng He~1 Fei-Zhou He~2 Can-Rong Wu~3 Shun-Xiang Li~2 Wei-Xin Liu~4 Yong-Fang Yang~2 Shi-Sheng Jiang~2 Gang He~1 1 Institute of Combined Traditional Chinese and Western Medicine,Xiangya Hospital,Hunan Medical University,Changsha,410008,China2 Hunan Province Academy of Traditional Chinese Medicine,Changsha 410006,China3 Department of Microbiology,Hunan College of Traditional Chinese Medicine,Changsha 410007,China4 Department of Pediatrics,The Second Hospital of Shuangfeng County,Hunan Province,411700,China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第5期735-740,共6页
AIM To observe the effects of Qiwei Baizhu Powder ( QWBZP) on rotaviral gastroenteritis in children and in animal models.``METHODS Enrolled patients were divided into two groups, and one group was treated with oral re... AIM To observe the effects of Qiwei Baizhu Powder ( QWBZP) on rotaviral gastroenteritis in children and in animal models.``METHODS Enrolled patients were divided into two groups, and one group was treated with oral rehydration solution(ORS) and the other treated with oral liquid of QWBZP. Neonate mice were orally infected with 50 μLrotavirus suspension (4 × l0s PFU/mL) and treated with ORS or oral liquid of QWBZP, respectively.``RESULTS Eighty-three cases of rotaviral gastroenteritis treated with QWBZP revealed a better efficacy than that treated with ORS (x2 - 10.8T, P<0.05). The contents of sodium and glucose as well as number of patients with positive human rotavirus antigen in stool in QWBZP group were all less than that in ORS group. In animal models,QWBZP was found effective in treating rotavirus gastroenteritis in neonate NIH mice, as compared with control groups. In QWBZP group, the mortality of infected mice was decreased by 73.3%, the body weight of infected mice was increased, the contents of sodium and glucose as well as number of mice with positive rotavirus antigen in feces were significantly reduced, and the pathological changes such as damage of small intestinal mucosa and villi were also obviously alleviated.``CONCLUSION QWBZP has effects on improving the absorptive function of small intestine, shortening the duration of diarrhea and rotavirus shedding from stool and alleviating the pathological changes of small intestine induced by rotavirus. 展开更多
关键词 gastroenteritis/drug THERAPY ROTAVIRUS infectionsdrug therapy: Qiwei baizhu powder/therapeutic use disease models ANIMAL
下载PDF
Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children
6
作者 Roberto Caete Angel A Escobedo +1 位作者 María E González Pedro Almirall 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第39期6366-6370,共5页
AIM: To compare the efficacy and safety of five days apostrophe therapy of mebendazole (MBZ) versus quinacrine (QC) on human giardiasis in children.METHODS: A clinical trial was carried out in paediatric patien... AIM: To compare the efficacy and safety of five days apostrophe therapy of mebendazole (MBZ) versus quinacrine (QC) on human giardiasis in children.METHODS: A clinical trial was carried out in paediatric patients (aged 5-15 years) with confirmed symptomatic G. duodenalis mono-infection. Patients were randomly assigned to receive either MBZ [200 mg taken three times per day GRID) (n = 61)] or QC [2 mg/kg bodyweight tid (n = 61)], both for five days. Follow-up faecal samples were obtained at 3, 5 and 7 d after the end of the treatment.RESULTS: Although the frequency of cure was higher for QC (83.6%) than for MBZ (78.7%), the difference was not statistically significant (P 〉 0.05). Adverse events were reported more in the QC group (P 〈 0.05), all of them transient and self-limiting.CONCLUSION: Despite final cure rates ocurring lower than expected, the overall results of this study reconfirmed the efficacy of MBZ in giardiasis and also indicate that, although comparable to QC, at least in this setting the 5 d course of MBZ did not appear to improve the cure rates in this intestinal parasitic infection. 展开更多
关键词 Giardia infection/drug therapy CHILDREN Me- bendazole/therapeutic use Quinacrine/therapeutic use Benzimidazoles/therapeutic use Giardiasis/drug therapy Cuba
下载PDF
Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer:A case report
7
作者 Che Hseuh Yang Kuo Tung Chen +3 位作者 Yi Sheng Lin Chao Yu Hsu Yen Chuan Ou Min Che Tung 《World Journal of Clinical Cases》 SCIE 2020年第20期4883-4894,共12页
BACKGROUND Target therapy is licensed by United States Food and Drug Administration on certain cancers.Both sorafenib and lenvatinib are tyrosine kinase inhibitor and indicated on radioactive iodine(RAI)-refractory di... BACKGROUND Target therapy is licensed by United States Food and Drug Administration on certain cancers.Both sorafenib and lenvatinib are tyrosine kinase inhibitor and indicated on radioactive iodine(RAI)-refractory differentiated thyroid cancer(DTC).Lenvatinib is more effective in cancers'control than sorafenib,but causes more nephrotoxicity than sorafenib does.This case is the second published case about the serial adaptions from lenvatinib to sorafenib for improving the proteinuria and,meanwhile,achieving the therapeutic goal.CASE SUMMARY A 56-year-old man suffered from bilateral edematous lower extremities after 1-mo prescription of lenvatinib of 20 mg/d for RAI-refractory DTC.Aside from this symptom,he also developed hypertension.His laboratory showed grade-3 proteinuria(estimated 24-h urine protein:9993 mg),hypoalbuminemia and hypercholesterolemia.Anti-vascular endothelial growth factor(VEGF)therapyinduced nephrotic syndrome was impressed.After reduced dosage of lenvatinib of 10 mg/d and related symptomatic drugs,limited improvement was observed in both adverse effects and caner control.Under this condition,we substituted sorafenib of 400 mg/d for lenvatinib of 10 mg/d.After a 5-mo prescription,not only hypertension and peripheral edema were greatly improved,but also proteinuria was improved from grade three to grade one(estimated 24-h urine protein:962 mg).At the same time the cancer control was achieved,judged from computed tomography and laboratory evidence[thyroglobulin(Tg)before prescription of sorafenib:354.7 ng/m L;Tg after prescription of sorafenib:108.9 ng/m L].CONCLUSION Adaption from lenvatinib to sorafenib is a feasible method to improve the antiVEGF therapy-induced nephrotic syndrome and achieve the therapeutic goal at the same time. 展开更多
关键词 Molecular targeted therapy/methods RECEPTORS Vascular endothelial growth factor/drug effects Vascular endothelial growth factor/therapeutic use Vascular endothelial growth factor A/drug effects Nephrotic syndrome/drug therapy Case report
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部